AG真人官方

Form 8-K 鈥� Item 8.01. AIM ImmunoTech (AIM) disclosed a mid-year update from its ongoing Phase 2 DURIPANC trial evaluating Ampligen (rintatolimod) + AstraZeneca鈥檚 Imfinzi (durvalumab) in metastatic pancreatic cancer patients who achieved stable disease after FOLFIRINOX.

The Company characterizes the interim results as 鈥減ositive,鈥� but the filing does not provide numerical response, progression-free-survival or safety data. Full details are contained in Exhibit 99.1 (press release) and Exhibit 99.2 (clinical progress deck), which are incorporated by reference.

Investment takeaways:

• Positive clinical signal in a high-mortality indication may raise Ampligen鈥檚 probability of success and strengthen AIM鈥檚 oncology pipeline narrative.
• Collaboration with AstraZeneca lends external validation.
• No financial metrics, partnership economics or guidance were announced; commercial impact remains distant and dependent on future trials and regulatory approvals.
• Forward-looking-statement language underscores unresolved clinical, regulatory and funding risks.

AIM ImmunoTech has filed Amendment No. 4 to its Form S-1 to sell up to 1,052,631 Units鈥攅ach containing one share (or a pre-funded warrant) plus a five-year Class E warrant and an 18-month Class F warrant鈥攁t an assumed $9.50 per Unit for gross proceeds of about $10 million. Maxim Group is acting on a reasonable best-efforts basis, earning a 7 % cash fee and placement-agent warrants equal to 5 % of the Units.

Estimated $9 million net proceeds will be directed to:

• working capital and payables
• clinical programs for Ampligen (pancreatic cancer, ME/CFS, post-COVID)
• manufacturing
• early repayment of a $310 k Streeterville bridge note

The company executed a 1-for-100 reverse split on 12 Jun 2025; trading on NYSE American resumed 17 Jun under 鈥淎IM.鈥� Shares outstanding would rise from 0.764 m to 1.817 m post-offering, lifting as-adjusted book value from 鈥�$8.47 to $1.63 but creating immediate dilution of $7.87 per share.

At 31 Mar 2025 AIM鈥檚 stockholders鈥� equity was 鈥�$3.9 m, below the exchange鈥檚 $6 m threshold. The NYSE American has accepted a compliance plan running to 11 Jun 2026; successful capital raising is pivotal. The filing reiterates a going-concern warning, notes that the offering lacks a minimum or escrow, and highlights liquidity risks if proceeds fall short.

Nasdaq Stock Market LLC filed Form 25 on 21 Jul 2025 to remove Procaps Group, S.A. (symbol PROCW) ordinary shares and warrants from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The filing states Nasdaq has complied with Rule 12d2-2 requirements and is therefore entitled to strike these classes from its rolls. No financial data, cause for delisting, or company commentary accompanies the notice. After the SEC鈥檚 standard 10-day review period, the securities will cease trading on Nasdaq; 90 days later, registration ends unless the SEC objects. Investors should note only the administrative fact of delisting鈥攏o other material corporate developments are disclosed.

AIM ImmunoTech Inc. ("AIM") has filed a Form S-8 to register 15,283 additional shares of common stock for issuance under its Amended and Restated 2018 Equity Incentive Plan. The newly registered shares result from the plan鈥檚 evergreen provision, which automatically increases the share pool each 1 July by 2% of the company鈥檚 then-outstanding common stock. The filing incorporates by reference six prior S-8 registrations and the company鈥檚 periodic SEC reports, thereby limiting new disclosure to the incremental share registration and updated exhibits.

The Form S-8 is a routine administrative filing that enables AIM to continue granting equity awards to employees, directors and consultants without preparing a separate prospectus for each issuance. Key exhibits include the plan document, legal opinions and auditor consents. Because only 15,283 shares are being added, the transaction represents a small potential dilution to existing shareholders while supporting AIM鈥檚 ability to attract and retain talent through equity incentives.

AIM ImmunoTech Inc. (NYSE American: AIM) has filed Amendment No. 3 to its Form S-1 to register a reasonable best-efforts offering of up to 1,052,631 Units at an assumed $9.50 per Unit, for gross proceeds of approximately $10 million and estimated net proceeds of ~$9 million. Each Unit comprises one share (or one pre-funded warrant) plus one five-year Class E warrant and one 18-month Class F warrant, both exercisable at 100 % of the public offering price. The Units are immediately separable; the warrants and pre-funded warrants will not be listed.

Key corporate actions and capital structure:

• Reverse split: 1-for-100 effected 12 June 2025; trading resumed on NYSE American 17 June 2025.
• Shares outstanding: 764,188 post-split (prior to the offering); 1,816,819 pro forma if all Units are sold and no warrants exercised.
• Capitalization (31 Mar 2025): cash & equivalents $2.247 m; stockholders鈥� equity negative $3.857 m; short-term debt $1.95 m (includes Streeterville note).
• Recent financing: $310 k unsecured bridge loan from Streeterville Capital on 30 Jun 2025 (net $250 k, OID $50 k, due in 120 days; early-pay discount possible); prior $3.301 m note maturing Feb 2026 with $250 k monthly payments (currently paid in stock).

Listing and regulatory status:

• AIM is not in compliance with NYSE American equity requirement (<$6 m equity). The exchange accepted a remediation plan requiring compliance by 11 June 2026; failure could lead to delisting.
• The company qualifies as a smaller reporting company and uses reduced disclosure requirements.

Use of proceeds (priority order): clinical program advancement, manufacturing costs, payables, potential repayment of Streeterville note or early-payment discount, and general working capital. There is no minimum raise, no escrow, and the placement agent (Maxim Group) will receive a 7 % cash fee plus warrants for 5 % of Units sold.

Risk profile highlights from the filing:

• Going-concern uncertainty due to accumulated deficits and negative equity.
• Potential dilution; illustrative dilution $7.87 per share at assumed pricing.
• Possible delisting if equity rule not satisfied.
• No active market expected for the newly issued warrants or pre-funded warrants.

The amendment reflects the reverse split, trading suspension and reinstatement, and updates capitalization and dilution tables accordingly.

AIM ImmunoTech Inc. (NYSE American: AIM) has filed Amendment No. 1 to its Form S-3 shelf registration statement, seeking authorization to issue up to $100 million of securities. The registration covers a wide variety of instruments鈥攊ncluding common and preferred stock, debt securities (senior, senior subordinated or subordinated, convertible or non-convertible), warrants, purchase contracts, subscription rights, depositary shares and units鈥攁llowing management to access capital 鈥渇rom time to time鈥� and in multiple tranches.

The company is classified as a non-accelerated filer and a smaller reporting company; it is not an emerging growth company. AIM鈥檚 common stock last traded at $9.50 on 23 June 2025. Specific terms (pricing, size, use of proceeds, underwriting arrangements) will be detailed in future prospectus supplements when individual offerings are launched.

Because the filing is a shelf registration under Rule 415, the statement enables AIM to move quickly when market conditions are favorable. However, the document also cautions investors that the information is preliminary and subject to change until the SEC declares the registration effective. Standard risk disclosures and forward-looking-statement safe-harbor language are included, and investors are directed to the company鈥檚 latest 10-K and subsequent filings for detailed risk factors.

Key takeaways for investors:

• Financing flexibility: Up to $100 million aggregate offering amount across multiple security types.
• Dilution potential: Common-equity issuance could dilute existing shareholders, depending on the mix ultimately chosen.
• Timing unknown: Securities may be issued 鈥渇rom time to time鈥� after effectiveness; no immediate issuance timetable is provided.
• No earnings data: The filing does not include current operating results or guidance; it strictly pertains to capital-markets authority.

AIM ImmunoTech received a warning notification from NYSE American on June 17, 2025, regarding non-compliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of -$3.9 million as of March 31, 2025, falling short of the required:

• $4.0 million minimum for companies with losses in 3 of 4 recent fiscal years
• $6.0 million minimum for companies with losses in 5 most recent fiscal years

This follows a previous warning from December 17, 2024. The NYSE American has accepted AIM's compliance plan, giving the company until June 11, 2026 to meet requirements. Trading continues under symbol "AIM" without interruption, and the warning does not affect business operations or SEC reporting requirements. The company's stock resumed trading on NYSE American on June 17, 2025.